ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
David Rice
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rice, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rice, D.
Related Collections
Right arrow Pleura
Right arrowRelated Article

Ann Thorac Surg 2006;82:2337-2338
© 2006 The Society of Thoracic Surgeons

Correspondence

Reply

David Rice, MB, BCh

University of Texas M.D. Anderson Cancer Center, Department of Thoracic and Cardiovascular Surgery, 1515 Holcombe Blvd, Box 445, Houston, TX 77030-4009

(Email: drice@mdanderson.org).

The first 20% of the full text of this article appears below.

To the Editor:

Doctor Aelony [1] raises several important points in his letter regarding our article [2]. Probably the most salient is that despite advances in chemotherapy, radiotherapy, and surgery for mesothelioma, current therapeutic regimens are rarely curative. Nonetheless in highly selected patients treated with aggressive multimodality regimens, several authors have documented survival that exceeds that associated with the natural course of the disease in untreated patients [3, 4]. Prospective, randomized comparative data are currently lacking; however the Mesothelioma and Radical Surgery (MARS) trial, now in pilot phase in Europe, will attempt to answer the question of whether survival is improved by chemotherapy, surgery, and radiation therapy compared with chemotherapy and supportive care alone. Until the results of this important phase III trial are available (expected to be complete in the year 2012), we will continue to have to make treatment decisions based on . . . [Full Text of this Article]


Related Article

Staging in Malignant Mesothelioma
Yossef Aelony
Ann. Thorac. Surg. 2006 82: 2337. [Extract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.